Actionable alterations were identified in 10.5% of patients (primarily by cell-free circulating DNA) from a realworld cohort of primarily advanced-stage lung squamous-cell carcinoma (LUSC). Objective response was observed in all 3 evaluable patients who received targeted therapy. Accurate histopathologic assessment in advanced LUSC can be challenging. Evaluating the genomic landscape in this setting is warranted to potentially identify underappreciated treatment options. Background: Major guidelines do not recommend routine molecular profiling of lung squamous-cell carcinoma (LUSC) because the prevalence of actionable alterations is thought to be low. Increased utilization of next-generation sequencing (NGS), particularly with cell-free circulating tumor DNA, facilitates reevaluation of this premise. Patients and Methods: We retrospectively evaluated the prevalence of actionable alterations in 2 distinct LUSC cohorts totaling 492 patients. A total of 410 consecutive patients with stage 3B or 4 LUSC were tested with a targeted cell-free circulating DNA NGS assay, and 82 patients with LUSC of any stage were tested with a tissue NGS cancer panel. Results: In the overall cohort, 467 patients (94.9%) had a diagnosis of LUSC, and 25 patients (5.1%) had mixed histology with a squamous component. A total of 10.5% of the LUSC subgroup had somatic alterations with therapeutic relevance, including in EGFR (2.8%), ALK/ROS1 (1.3%), BRAF (1.5%), and MET amplification or exon 14 skipping (5.1%). Sixteen percent of patients with mixed histology had an actionable alteration. In the LUSC subgroup, 3 evaluable patients were treated with targeted therapy for an actionable alteration; all of them experienced partial response. Conclusion: In this large, real-world LUSC cohort, we observed a clinically significant prevalence of actionable alterations. Accurate local histopathologic assessment in advanced-stage LUSC can be challenging. Further evaluation of the genomic landscape in this setting is warranted to potentially identify underappreciated treatment options.
Introduction
Lung squamous-cell carcinoma (LUSC) is the second most common histology (20%-25%) of nonesmall-cell lung cancer in the United States and worldwide. 1, 2 While there have been substantial advances over the past decade in targeted treatments for lung adenocarcinoma, vascular endothelial growth factor and epidermal growth factor receptor (EGFR) monoclonal antibodies represent the only US Food and Drug Administration (FDA)-approved targeted therapies in LUSC and have provided modest survival benefit. 3, 4 Actionable genomic alterations, generally defined here as somatic alterations that have a demonstrated clinical response to FDAapproved or investigational therapies, occur in 20% to 60% of lung adenocarcinoma patients (depending on demographic factors). 5 In contrast, these alterations were historically thought to be rare in LUSC. Currently, genomic alterations in EGFR, ALK, ROS1, and BRAF have approved targeted treatment options for nonesmall-cell lung cancer patients. 6 Clinical activity has also been observed with agents targeting other alterations such as MET amplifications and exon 14 skipping, 7, 8 BRAF non-V600E mutations, 9 and RET and NTRK translocations. 10, 11 These actionable alterations have been observed at a lower rate in LUSC, although the reported prevalence has varied across studies. In the panelung cancer whole-exome sequencing LUSC cohort (comprised primarily of resected specimens, including samples previously published by The Cancer Genome Atlas Research Network), actionable alterations in EGFR (0.8%), MET (exon 14 skipping [0.2%] or amplification [1%]), and BRAF (1.2%) appear to be uncommon. 12 In other LUSC cohorts tested by conventional molecular profiling methods such as immunohistochemistry (IHC), PCR, fluorescence in-situ hybridization (FISH), and RNA expression, EGFR (0%) mutations and ALK (0%-1.4%), ROS1 (0%), and RET (0%) rearrangements were rare. [13] [14] [15] [16] [17] However, a much higher rate of EGFR sensitizing mutations have been recently reported in advanced LUSC tumors, including in 6% of stage IIIB and IV LUSC patients from LUX-8, a phase 3 clinical trial. 18 However, only half of these were EGFR mutations of known clinical significance. Furthermore, a separate analysis showed improved progression-free and overall survival in the subset of patients with ERBB gene alterations treated with a pan-ERBB inhibitor. 19 Additionally, 2.1% of an LUSC cohort exhibited MET exon 14 skipping as detected by tissue next-generation sequencing (NGS). 20 Difficulty in the accurate histopathologic diagnosis of LUSC may be a reason for disparate findings across case series. For example, poorly differentiated adenocarcinomas with a solid growth pattern are not common but can resemble LUSC. During central pathology review, 17% of (primarily resected) tumors submitted as LUSC to The Cancer Genome Atlas project were reclassified as nonsquamous. 21 Challenges in accurate diagnosis are likely exacerbated in the metastatic setting, as reliance on small biopsy specimens may incompletely sample mixed adenosquamous histology. 13 These issues lead to high interobserver variability and have resulted in updated recommendations for IHC staining in all cases of solid adenocarcinoma and nonkeratinizing squamous-cell carcinoma. 22, 23 While current guidelines do allow for consideration of EGFR, ALK, and ROS1 testing in cases of never smokers, small biopsy specimens, and mixed histology or in patients with other clinical features that may suggest a higher probability of an oncogenic driver (eg, younger age), routine comprehensive molecular profiling is currently not recommended for LUSC. 6, 24 Notably, BRAF and MET exon 14 mutations may actually be more common in smokers. 25, 26 Given increased accessibility and utilization of comprehensive NGS, particularly with cell-free circulating DNA (cfDNA), we sought to reevaluate the prevalence of actionable alterations in a primarily metastatic cohort, where histopathologic challenges are often accentuated and targeted therapies for these alterations are typically employed. Additionally, we aimed to characterize the pattern of single nucleotide variants (SNVs) and copy number amplifications (CNAs) obtained by targeted cfDNA NGS and compare it to the previously described genomic landscape of LUSC.
Patients and Methods

Study Design
We retrospectively evaluated the prevalence of actionable alterations in 2 distinct LUSC cohorts totaling 492 patients. Circulating Tumor DNA Landscape
In order to compare the landscape of all nonsynonymous alterations detected by the cfDNA assay with the known tissue landscape of LUSC, we accessed SNV, indel, and copy-number variation data from the panelung cancer cohort of 484 LUSC patients via cBioPortal.
12,33,34
Statistical Analysis
We tested categorical associations (eg, sex) between patients with and without actionable alterations by the Fisher exact test. For SNVs and CNAs of greatest significance in LUSC, we evaluated the frequency correlation between our cfDNA cohort and the panelung cancer cohort by the Spearman rank test. All statistical tests were 2 sided. Two-tailed P < .05 was considered to be statistically significant. Statistical analyses were conducted using GraphPad Prism 7 software. This retrospective study was conducted in accordance with the institutional review board at the University of Texas MD Anderson Cancer Center. Table 1 shows the baseline clinical characteristics of the patients in this study. Generally consistent with known epidemiology of LUSC, most of the patients in our study were male (60.8%) and with median age of 69 at time of testing. Smoking history was not reported in the cfDNA cohort, but patients in the MDACC cohort had a median 42 pack-year smoking history. The overwhelming majority of the patients in our study had metastatic disease (94.9%) and no mixed histology per their formal pathology report (94.9%). Central pathology review was not performed in this study. Patients in the MDACC cohort were generally diagnosed by morphology only.
Results
Baseline Characteristics
Most cfDNA samples (75.5%) were analyzed with the 70-gene panel. The vast majority of cfDNA patients (96.3%) were tested at only a single time point. The cfDNA sample was drawn a median of 284 days (and average of 499 days) from the time of diagnosis (data available for 46% of cases). A total of 379 cfDNA patients (92.4%) had at least one somatic alteration detected.
Actionable Alterations in LUSC Subgroup
The prevalence of patients with actionable alterations in our overall study cohort was 10.0%. This includes a small number of cases with mixed-squamous histology, as described below. In order to best address the clinically relevant question of actionable alterations in LUSC, we restricted our major analyses to cases that had no mention of mixed histology (ie, the LUSC subgroup).
When considering only the 467 patients in the LUSC subgroup, 10.5% (cfDNA 12.2%, MDACC 8.5%) had somatic alterations with therapeutic relevance ( Table 2 ). The median age (68) of these patients with actionable alterations is consistent with that of the overall study cohort. There was a trend towards an association between female sex and the presence of actionable alterations in squamous patients (hazard ratio ¼ 1.70; 95% confidence interval, 0.92-3.05; P ¼ .09). MDACC squamous patients with actionable alterations collectively had a median smoking history of 25 packyears. MET amplifications and EGFR SNVs/indels were the most common actionable alterations identified (4.3% and 2.8%, respectively). Activating BRAF mutations were next most common (1.5% of patients) though none with V600E, followed by MET exon 14 skipping (1.3%), ALK fusions (0.9%), and ROS1 fusions (0.4%). RET fusions were not detected in the cfDNA cohort and were not tested in the MDACC cohort. Notably, ALK rearrangements and EGFR alterations were most common (combined 4.9% of patients) in the MDACC cohort. Of the 7 patients with actionable alterations in the MDACC cohort, molecular profiling was performed at time of diagnosis and upon metastatic recurrence for 5 and 2 patients, respectively. All of these patients had molecular testing on tissue obtained from their initial diagnosis or resection. None had prior targeted therapy.
Concomitant actionable alterations were rare (Figure 1 ). In the cfDNA cohort, there were 5 patients with actionable comutations (1.1% of LUSC subgroup), all involving EGFR alterations. The EGFR coalterations were primarily EGFR exon 19 deletions comutated with T790M and/or C797S resistance mutations. Another patient had EGFR L858R/T790M and MET 
Minor Impact of Mixed-Squamous Histology
The MDACC cohort had no cases of mixed histology. There was a small percentage of patients with mixed-squamous histology in the cfDNA cohort (25 patients, 6.1%). Seventy-two percent of these cases were adenosquamous (3.7% of overall study cohort). The rest were classified as mixed glandular and squamous (3 patients), neuroendocrine and squamous (1 patient), large cell carcinoma and squamous (2 patients), and poorly differentiated squamous with possible urothelial features (overall clinical picture consistent with lung primary; 1 patient). In this mixed-squamous subset of 25 patients, we observed 6 actionable alterations in 4 patients (16% of mixed histology patients). All of those alterations had adenosquamous histology and involved EGFR SNVs or indels, including 2 patients with T790M concurrent with their driver mutation.
Clinical Response to Targeted Therapy
Clinical outcome data were generally not available for patients in the cfDNA cohort. However, we were able to obtain clinical details for a select patient in that cohort (Supplemental Table 3 in the online version). This patient had IHC-confirmed LUSC (TTF-1 negative, p40 and p63 positive) and cfDNA-detected EZR-ROS1 fusion that was subsequently verified by tissue NGS analysis. She had a major partial response, per Response Evaluation Criteria in Solid Tumors v1.1, to crizotinib that has persisted for over 10 months. 35 For the 7 patients in the MDACC cohort with actionable mutations, 4 have not yet been treated with the associated targeted therapy due to adequate disease control from other treatment. Of the patients who have been treated with targeted therapy, one patient had very limited ALK inhibitor exposure because of intractable drug related gastrointestinal toxicity and was considered not to be evaluable for the purposes of this analysis. Two patients with separate sensitizing EGFR exon 19 deletions (detected in both cfDNA and tissue) achieved partial response. The first of these patients had a total of 23 months of disease control on erlotinib and then afatinib. The second patient recently started erlotinib, with partial response after 2 months.
Tissue and cfDNA NGS Concordance
Previous retrospective studies (including one with over 15,000 patients) have demonstrated concordance between tissue and cfDNA NGS-detected alterations (tested on the Guardant platform) in the range of 70% to 87%. 31, [36] [37] [38] Due to the limited number of patients in our overall cohort that had both tissue and cfDNA NGS testing, concordance analysis was not possible in this study. For all 3 cases in our cohort that did have tissue and cfDNA NGS results, the respective driver alteration was detected by both modalities (Supplemental Table 3 in the online version).
Somatic cfDNA Landscape of LUSC
Overall, the frequency of SNVs and CNAs in cfDNA positively correlates with the panelung cancer LUSC cohort (Spearman r ¼ 0.62, P < .001). All nonsynonymous SNVs were included in this comparison, regardless of clinical relevance. In cfDNA, the most commonly observed SNVs were in TP53 (62.6%), NF1 (13.5%), PIK3CA (12.2%), ARID1A (11.9%), and EGFR (11.7%). Except for EGFR, all of these frequently mutated SNVs in the cfDNA cohort (frequency > 10%) are also considered to be particularly relevant in LUSC (q value < 0.1 per MutSig2CV analysis in panelung cancer LUSC data set) (Figure 2A ). The frequency of SNVs in cfDNA correlates with the panelung cancer LUSC cohort with near statistical significance (Spearman r ¼ 0.59, P ¼ .06, Figure 2B ).
The CNAs tested in our cfDNA panel that are considered significant in LUSC (q value < 0.25 per GISTIC 2.0 analysis in the panelung cancer LUSC data set) are EGFR, FGFR1, MYC, CCNE1, CDK6, ERBB2, PDGFRA, CCND1, KIT ( Figure 3A) . Amplifications in PDGFRA, CCND1, KIT were not frequently seen. The frequency of CNAs correlates between cfDNA and the Figure 3B ).
Discussion
Actionable driver alterations in genes such as EGFR, ALK, and KRAS are known to be present at lower rates in LUSC than LUAD, although the existing data are derived primarily from surgically resected, early stage LUSC, typically with central pathology review. There are limited data regarding the frequency of targetable alterations in advanced LUSC patients diagnosed in a real-world, or predominantly community-based, setting. Molecular profiling is not routinely obtained for LUSC and the use of targeted therapies directed at genomic alterations has been limited in this histology. However, the increased utilization of comprehensive NGS by cfDNA in clinical practice presents an opportunity to profile advanced-stage disease in a large-scale manner and facilitates reexamination of the prevalence of actionable alterations in LUSC.
The real-world population assessed here differs in important ways from the predominantly early stage, surgically resected tumors reported in the panelung cancer project. In this study, the lack of central pathology review and the dependence on generally more limited tissue specimens increases the likelihood of greater variability in the diagnosis of LUSC. This is more representative of the range of advanced LUSC tumors that are treated with systemic therapies in clinical practice. Well-known challenges in the histopathologic diagnosis of LUSC suggest that the true prevalence of actionable alterations may be lower than what was observed in our real-world cohort. However, the prevalence of actionable alterations in the tertiary-care, single-institution subgroup (MDACC cohort) is comparable to that of the cfDNA cohort, suggesting that any reclassification of Tumor DNA Sequencing histology upon central testing likely would not significantly impact the overall magnitude and clinical implications of our findings. If there was significant reclassification of histology in the study cohort, this would underscore the on-going difficulties in LUSC diagnosis in advanced-stage disease and the potential peril of limiting genomic profiling in patients diagnosed with this histology.
We only have limited patient-level data for the cfDNA cohort that comprises the majority of our study. Thus, we are not able to make major conclusions about other clinical characteristics that may be associated with actionable alterations in LUSC (such as smoking history) or comprehensively assess clinical outcomes for patients who may have been treated with appropriate targeted therapy. Three patients in the cohort that have been treated with targeted therapy and were evaluable for response; all 3 had measurable disease response.
Compared to prior LUSC studies that were limited by conventional molecular profiling or focused on resected/early-stage disease, our cohort of primarily advanced-stage LUSC patients tested mostly with cfDNA NGS may better represent the impact of metastatic disease, intratumor heterogeneity, and practical challenges in the histopathologic diagnosis of LUSC. The clinically significant prevalence of actionable alterations that we observed suggest that there are underappreciated treatment options in patients diagnosed with LUSC in the real-world setting. This hypothesis will be directly evaluated in the on-going Lung Cancer Master Protocol (Lung-MAP), which includes genomic profiling from advanced LUSC patients (using both cfDNA and tissue NGS) in a clinical trial framework testing different targeted and immune therapies. 39 
Conclusion
Targeted therapy in LUSC is an unmet need. In our cohort of LUSC patients, comprehensive NGS revealed a clinically significant prevalence of actionable alterations in 10.5% of patients. Additionally, we observed that SNVs and CNAs from cfDNA profiling were largely consistent with the known tissue LUSC landscape. Our findings suggest that routine genomic profiling in advanced LUSC merits further evaluation to potentially uncover underappreciated treatment options in a setting where accurate histopathologic assessment has well-known challenges. Moreover, advanced-stage LUSC patients should continue to be included in appropriate matched therapy studies in order to build upon these findings and expand the overall understanding of outcomes from targeting molecular driver alterations in LUSC.
Clinical Practice Points
Major guidelines currently do not recommend routine molecular profiling for LUSC. Actionable alterations in LUSC are thought to be rare. However, those data are primarily derived from resected specimens tested at large academic centers. There are limited data regarding the frequency of targetable alterations in advanced LUSC patients diagnosed in a real-world setting. This is relevant because there are well-known challenges in the histopathologic diagnosis of LUSC. We report a clinically significant prevalence of actionable alterations in a large, real-world LUSC cohort. These alterations represent underappreciated treatment options and suggest that the prevalence actionable alterations in advanced LUSC should be further evaluated. CCNE1  MAP2K1  RHEB  RB1  TSC1  BRAF  CDH1  CDKN2A  CSF1R  CTNNB1  EGFR  ARID1A  CDK4  MAP2K2  RHOA  ERBB2  ERBB4  EZH2  FBXW7  FGFR1  FGFR2  BRCA1  CDK6  NF1  RIT1  FGFR3  FLT3  GNA11  GNAQ  GNAS  HNF1A  BRCA2  CDKN2B  NFE2L2  ROS1  HRAS  IDH1  IDH2  JAK2  JAK3  KDR  CCDN1  ESR1  NTRK1  KIT  KRAS  MET  MLH1  MPL  MYC  CCND2  GATA3  RAF1  NOTCH1  NPM1  NRAS  PDGFRA  PIK3CA  PROC  PTEN  PTPN11  RB1  RET  SMAD4  SMARCB1  SMO  SRC  STK11  TERT  TP53  VHL   CNAs  EGFR  ERBB2  MET  AR  BRAF  CCNE1  CDK4  CCND1  CCND1  CDK8  FGFR1  FGFR2  KIT  KRAS  MYC  PDGFRA  PIK3CA 
